US Stock MarketDetailed Quotes
JANX Janux Therapeutics
- 66.835
- +6.975+11.65%
Close Dec 4 16:00 ET
- 66.803
- -0.033-0.05%
Post 20:01 ET
3.51BMarket Cap-57123P/E (TTM)
70.030High56.710Low4.04MVolume60.000Open59.860Pre Close264.30MTurnover10.63%Turnover RatioLossP/E (Static)52.48MShares71.25052wk High5.35P/B2.54BFloat Cap7.79052wk Low--Dividend TTM38.03MShs Float71.250Historical High--Div YieldTTM22.25%Amplitude5.650Historical Low65.364Avg Price1Lot Size
About Janux Therapeutics Company
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
Company Profile
SymbolJANX
Company NameJanux Therapeutics
Listing DateJun 11, 2021
Issue Price17.00
Founded2017
CEODr. David Campbell, PhD
MarketNASDAQ
Employees64
Fiscal Year Ends12-31
Address11099 North Torrey Pines Park,Suite 290
CityLa Jolla
ProvinceCalifornia
CountryUnited States of America
Zip Code92037
Phone1-858-750-4700
Websitehttp://www.januxrx.com
Company Executives
- Name
- Position
- Salary
- Dr. David Campbell, PhD
- Director, President and Chief Executive Officer
- 4.19M
- Charles M. Winter
- Chief Technical Officer
- 1.61M
- Tighe Reardon
- Acting Chief Financial Officer and Principal Accounting Officer
- --
- Andy Meyer
- Chief Business Officer
- --
- Dr. Tommy DiRaimondo, PhD
- Chief Scientific Officer
- --
- Dr. Byron Robinson, PhD
- Chief Strategy Officer
- 1.74M
- Dr. Ronald W. Barrett, PhD
- Chairman of the Board
- 162.69K
- Eric L. Dobmeier
- Director
- --
- Dr. Sheila Gujrathi, M.D.
- Director
- 158.01K
- Natasha A. Hernday
- Director
- --
- Alana B. McNulty
- Independent Director
- 166.57K
- Vickie L. Capps
- Independent Director
- 173.01K
- Winston Kung, M.B.A.
- Independent Director
- 164.77K
- Dr. Jake Sin, PhD
- Independent Director
- 172.07K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
